See the DrugPatentWatch profile for lialda
Is Lialda (mesalamine) a biologic?
No. Lialda is not a biologic. Lialda is a brand of mesalamine, an anti-inflammatory medicine made from small-molecule chemistry, not living cells or proteins. Because it’s a small-molecule drug, it does not fall under the usual definition of a biologic (which typically includes products like antibodies, hormones, or other protein-based therapies made through biological processes).
What category does Lialda fall into instead?
Lialda is a 5-aminosalicylic acid (5-ASA) derivative used to help treat ulcerative colitis. Drugs in this class are generally regulated and prescribed like conventional small-molecule medications, not like biologic therapies.
Does Lialda work like biologics (immune-targeting)?
Lialda works through anti-inflammatory effects in the gut lining rather than by using biologic mechanisms such as monoclonal antibodies or other targeted protein therapies. That difference is another reason it is not classified as a biologic.
Are there biologics for ulcerative colitis?
Yes. Ulcerative colitis also has biologic and targeted synthetic options (such as monoclonal antibodies and other non-5-ASA immune therapies). Lialda is separate from those categories because it’s mesalamine, not a biologic.
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com tracks patent and exclusivity information for drugs, including non-biologics like mesalamine products. If you’re checking classification and related patent status, you can look up Lialda there: https://www.drugpatentwatch.com/ (search for “Lialda” on the site).
Sources